New β-Lactamase Inhibitors in the Clinic

Overview

Journal Infect Dis Clin North Am

Specialty Infectious Diseases

Date 2016 May 22

PMID 27208767

Citations 80

Authors

Krisztina M Papp-Wallace

Robert A Bonomo

Affiliations

Soon will be listed here.

Abstract

Given the serious medical burden of β-lactamases, many approaches are being used identify candidate agents for β-lactamase inhibition. Here, we review two β-lactam-β-lactamase inhibitor (BL-BLI) combinations, ceftolozane-tazobactam and ceftazidime-avibactam that recently entered the clinic. In addition, we focus on BL-BLI combinations in preclinical development that have demonstrated activity in clinical isolates via susceptibility testing and/or in in vivo models of infection. We highlight only the BLIs that are able to reduce the Clinical Laboratory Standards Institute (CLSI) breakpoints for the BL partner into the susceptible range. Our analysis includes the primary literature, meeting abstracts, as well as the patent literature.

Citing Articles

Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.

Myers C, Stevenson A, Miller B, Daigle D, Uehara T, Pevear D Antimicrob Agents Chemother. 2025; 69(3):e0151124.

PMID: 39927783 PMC: 11881561. DOI: 10.1128/aac.01511-24.

Approachable Synthetic Methodologies for Second-Generation -Lactamase Inhibitors: A Review.

Fatima N, Khalid S, Rasool N, Imran M, Parveen B, Kanwal A Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338273 PMC: 11434895. DOI: 10.3390/ph17091108.

Crystal structure of the class A extended-spectrum β-lactamase CTX-M-96 in complex with relebactam at 1.03 Angstrom resolution.

Ghiglione B, Rodriguez M, Penzotti P, Bethel C, Gutkind G, Bonomo R Antimicrob Agents Chemother. 2024; 68(8):e0172123.

PMID: 38990013 PMC: 11304709. DOI: 10.1128/aac.01721-23.

Machine Learning Models Identify Inhibitors of New Delhi Metallo-β-lactamase.

Cheng Z, Aitha M, Thomas C, Sturgill A, Fairweather M, Hu A J Chem Inf Model. 2024; 64(10):3977-3991.

PMID: 38727192 PMC: 11129921. DOI: 10.1021/acs.jcim.3c02015.

First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.

De la Cadena E, Mojica M, Rojas L, Castro B, Garcia-Betancur J, Marshall S Microbiol Spectr. 2024; 12(6):e0410523.

PMID: 38700337 PMC: 11237465. DOI: 10.1128/spectrum.04105-23.

References

Nishida K, Kunugita C, Uji T, Higashitani F, Hyodo A, Unemi N . In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother. 1999; 43(8):1895-900. PMC: 89387. DOI: 10.1128/AAC.43.8.1895. View

Powers R, Blazquez J, Weston G, Morosini M, Baquero F, Shoichet B . The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci. 1999; 8(11):2330-7. PMC: 2144209. DOI: 10.1110/ps.8.11.2330. View

Adediran S, Nukaga M, Baurin S, Frere J, Pratt R . Inhibition of class D beta-lactamases by acyl phosphates and phosphonates. Antimicrob Agents Chemother. 2005; 49(10):4410-2. PMC: 1251531. DOI: 10.1128/AAC.49.10.4410-4412.2005. View

Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K . Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007; 30(5):443-5. DOI: 10.1016/j.ijantimicag.2007.05.019. View

Poeylaut-Palena A, Tomatis P, Karsisiotis A, Damblon C, Mata E, Vila A . A minimalistic approach to identify substrate binding features in B1 Metallo-beta-lactamases. Bioorg Med Chem Lett. 2007; 17(18):5171-4. DOI: 10.1016/j.bmcl.2007.06.089. View

Majumdar S, Pratt R . Inhibition of class A and C beta-lactamases by diaroyl phosphates. Biochemistry. 2009; 48(35):8285-92. PMC: 2896318. DOI: 10.1021/bi900807e. View

Mushtaq S, Warner M, Livermore D . Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J Antimicrob Chemother. 2009; 65(2):266-70. DOI: 10.1093/jac/dkp425. View

Papp-Wallace K, Bethel C, Distler A, Kasuboski C, Taracila M, Bonomo R . Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother. 2009; 54(2):890-7. PMC: 2812178. DOI: 10.1128/AAC.00693-09. View

Blizzard T, Chen H, Kim S, Wu J, Young K, Park Y . Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. Bioorg Med Chem Lett. 2010; 20(3):918-21. DOI: 10.1016/j.bmcl.2009.12.069. View

10.

Drawz S, Bonomo R . Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010; 23(1):160-201. PMC: 2806661. DOI: 10.1128/CMR.00037-09. View

11.

Page M, Dantier C, Desarbre E . In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010; 54(6):2291-302. PMC: 2876421. DOI: 10.1128/AAC.01525-09. View

12.

Mushtaq S, Warner M, Williams G, Critchley I, Livermore D . Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010; 65(7):1428-32. DOI: 10.1093/jac/dkq161. View

13.

Lassaux P, Hamel M, Gulea M, Delbruck H, Mercuri P, Horsfall L . Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010; 53(13):4862-76. DOI: 10.1021/jm100213c. View

14.

Ishii Y, Eto M, Mano Y, Tateda K, Yamaguchi K . In vitro potentiation of carbapenems with ME1071, a novel metallo-beta-lactamase inhibitor, against metallo-beta-lactamase- producing Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2010; 54(9):3625-9. PMC: 2934957. DOI: 10.1128/AAC.01397-09. View

15.

Mushtaq S, Warner M, Livermore D . In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010; 65(11):2376-81. DOI: 10.1093/jac/dkq306. View

16.

Bou G, Santillana E, Sheri A, Beceiro A, Sampson J, Kalp M . Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc. 2010; 132(38):13320-31. PMC: 3393087. DOI: 10.1021/ja104092z. View

17.

Livermore D, Mushtaq S, Warner M . Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J Antimicrob Chemother. 2010; 65(11):2382-95. DOI: 10.1093/jac/dkq310. View

18.

Eidam O, Romagnoli C, Caselli E, Babaoglu K, Teotico Pohlhaus D, Karpiak J . Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J Med Chem. 2010; 53(21):7852-63. PMC: 3166525. DOI: 10.1021/jm101015z. View

19.

Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M . Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2010; 55(1):390-4. PMC: 3019623. DOI: 10.1128/AAC.00756-10. View

20.

Sakurai Y, Yoshida Y, Saitoh K, Nemoto M, Yamaguchi A, Sawai T . Characteristics of aztreonam as a substrate, inhibitor and inducer for beta-lactamases. J Antibiot (Tokyo). 1990; 43(4):403-10. DOI: 10.7164/antibiotics.43.403. View